Truist Securities Maintains Buy on Immunovant, Raises Price Target to $48-Report Released on 14th Nov 2023
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Robyn Karnauskas has maintained a Buy rating on Immunovant (NASDAQ:IMVT) and increased the price target from $30 to $48 as reported on November 14, 2023.
November 15, 2023 | 6:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities has reaffirmed a Buy rating on Immunovant and raised the price target from $30 to $48, indicating a positive outlook on the stock.
The increase in price target by a reputable analyst like Robyn Karnauskas from Truist Securities typically signals a strong conviction in the company's future performance and can lead to increased investor confidence, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100